Stock Track | Braveheart Bio Soars 67.78% in Debut After Upsized $383 Million IPO

Stock Track

08/07

Shares of Braveheart Bio Inc. (BRVE) soared 67.78% during intraday trading on Thursday, marking a stellar debut on the Nasdaq Global Market.

The surge comes after the clinical-stage biopharmaceutical company priced its upsized initial public offering at $18 per share, the high end of its marketing range. The company sold approximately 21.3 million shares, raising $382.5 million in gross proceeds, after increasing the deal size from 18.75 million shares and pricing above the initial $15 to $17 range. The strong investor demand for the offering fueled the significant first-day pop.

Braveheart Bio is focused on developing therapies for patients with hypertrophic cardiomyopathy and other serious cardiovascular diseases. The company intends to use the IPO proceeds to advance the development of its lead product candidate, BHB‑1893.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hans/news/1150536472"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1150536472\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1150536472?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-07 00:52","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1150536472","market":"nz","top_or_hot":-1,"title":"Stock Track | Braveheart Bio Soars 67.78% in Debut After Upsized $383 Million IPO","media":"Stock Track","content":"<p>Shares of Braveheart Bio Inc. (BRVE) soared 67.78% during intraday trading on Thursday, marking a stellar debut on the Nasdaq Global Market.</p><p>The surge comes after the clinical-stage biopharmaceutical company priced its upsized initial public offering at $18 per share, the high end of its marketing range. The company sold approximately 21.3 million shares, raising $382.5 million in gross proceeds, after increasing the deal size from 18.75 million shares and pricing above the initial $15 to $17 range. The strong investor demand for the offering fueled the significant first-day pop.</p><p>Braveheart Bio is focused on developing therapies for patients with hypertrophic cardiomyopathy and other serious cardiovascular diseases. The company intends to use the IPO proceeds to advance the development of its lead product candidate, BHB‑1893.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Braveheart Bio Soars 67.78% in Debut After Upsized $383 Million IPO</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Braveheart Bio Soars 67.78% in Debut After Upsized $383 Million IPO\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-08-07 00:52</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of Braveheart Bio Inc. (BRVE) soared 67.78% during intraday trading on Thursday, marking a stellar debut on the Nasdaq Global Market.</p><p>The surge comes after the clinical-stage biopharmaceutical company priced its upsized initial public offering at $18 per share, the high end of its marketing range. The company sold approximately 21.3 million shares, raising $382.5 million in gross proceeds, after increasing the deal size from 18.75 million shares and pricing above the initial $15 to $17 range. The strong investor demand for the offering fueled the significant first-day pop.</p><p>Braveheart Bio is focused on developing therapies for patients with hypertrophic cardiomyopathy and other serious cardiovascular diseases. The company intends to use the IPO proceeds to advance the development of its lead product candidate, BHB‑1893.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BRVE","symbol_name":"Braveheart Bio","start_time":0,"source_url":"","article_id":"1150536472","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1150536472","pubTimestamp":1786035174,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of Braveheart Bio Inc. (BRVE) soared 67.78% during intraday trading on Thursday, marking a stellar debut on the Nasdaq Global Market.The surge comes after the clinical-stage biopharmaceutical...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BRVE":"Braveheart Bio"},"translate_title":"股票追踪 | Braveheart Bio 首次公开募股规模扩大 3.83 亿美元后，首日股价飙升 67.78%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BRVE":1},"content_text":"Shares of Braveheart Bio Inc. (BRVE) soared 67.78% during intraday trading on Thursday, marking a stellar debut on the Nasdaq Global Market.The surge comes after the clinical-stage biopharmaceutical company priced its upsized initial public offering at $18 per share, the high end of its marketing range. The company sold approximately 21.3 million shares, raising $382.5 million in gross proceeds, after increasing the deal size from 18.75 million shares and pricing above the initial $15 to $17 range. The strong investor demand for the offering fueled the significant first-day pop.Braveheart Bio is focused on developing therapies for patients with hypertrophic cardiomyopathy and other serious cardiovascular diseases. The company intends to use the IPO proceeds to advance the development of its lead product candidate, BHB‑1893.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}